Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Liabilities from Discontinued Operations of 4931000000.0 for Q4 2013.
Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013) Analysis & Trends
Bristol Myers Squibb has disclosed Liabilities from Discontinued Operations across 1 years of filings, most recently posting 4931000000.0 for Q4 2013.
- In Q4 2013, Liabilities from Discontinued Operations changed N/A year-over-year to 4931000000.0; the TTM figure through Dec 2013 stood at 4931000000.0 (changed N/A YoY), while the FY2013 annual figure was 4931000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 4931000000.0 in Q4 2013.
- Over the last five years, Liabilities from Discontinued Operations for CELG-RI reached as high as 4931000000.0 in Q4 2013 and fell as low as 4931000000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 4.93 Bn |
| Dec 31, 2013 | 4.93 Bn |